Exclusive Summary

• Backed by US-FDA registration and GMP certification, offering global gold-standard quality to facilitate fast-track regulatory approvals in emerging markets via SRA reliance pathways.
• Addressing a massive global burden of over 50 million AFib patients, the originator represents an $18+ billion blockbuster market with sustained, high-volume demand.
• With global originator patents expiring between 2026 and 2028, securing an FDA-approved, ready-to-launch generic now guarantees distributors a highly lucrative first-mover advantage.
• Listed as a WHO Essential Medicine and strongly recommended by major guidelines as a first-line DOAC, its superior safety profile with lower bleeding risks ensures undeniable clinical acceptance.